A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy

Trial Profile

A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Jan 2018.
    • 10 Dec 2015 Accrual till date is 0% according to United Kingdom Clinical Research Network.
    • 17 Jul 2015 New source identified and integrated (European Clinical Trials Database record:EudraCT2012-004295-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top